文献速递血栓与止血

地塞米松联合奥司他韦对比地塞米松治疗初治原发性免疫性血小板减少症:多中心随机开放标签2期试验

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2021-01-01

该多中心随机开放标签2期试验纳入96例初治原发性免疫性血小板减少症成人患者,比较地塞米松联合奥司他韦与地塞米松单药的疗效与安全性。联合组14天初始反应率和6个月持续反应率均显著高于单药组,不良事件以1-2级为主,无治疗相关死亡。

要点

  • 联合组常见不良事件为疲劳、胃肠道反应、失眠和焦虑,无4-5级不良事件。

核心结论

  • 地塞米松联合奥司他韦可提高初治原发性免疫性血小板减少症患者的14天初始反应率和6个月持续反应率。
  • 该联合方案安全性可接受,无4-5级不良事件和治疗相关死亡。

研究设计与样本

  • 多中心、随机、开放标签、平行组2期试验,在中国五家三级医院进行。
  • 纳入96例18岁及以上新诊断、未治疗的原发性免疫性血小板减少症患者,随机1:1分配至地塞米松联合奥司他韦组(n=47)或地塞米松单药组(n=49)。
  • 改良意向性治疗分析纳入90例接受分配干预的患者。

主要发现

  • 中位随访8个月(IQR 5-14),两组各1例因3级严重不良事件停药(联合组全身水肿2%,单药组发热2%)。
  • 常见任何级别不良事件:疲劳(联合组12% vs 单药组17%)、胃肠道反应(19% vs 6%)、失眠(16% vs 9%)、焦虑(12% vs 6%)。

关键数值与推荐

  • 完全反应:血小板计数≥100×10^9/L且无出血。
  • 部分反应:血小板计数≥30×10^9/L但<100×10^9/L,且至少为基线两倍,无出血。
  • 持续反应:初始反应后至少6个月无额外原发性免疫性血小板减少症特异性干预。
  • 无反应(第10天血小板<30×10^9/L或出血)者追加一个周期地塞米松4天。

临床怎么用

  • 地塞米松联合奥司他韦可作为初治原发性免疫性血小板减少症的一种 readily available 联合治疗选择。
  • 对初始反应后复发者,可考虑补充奥司他韦疗程以维持血小板反应。

局限性

  • 2期开放标签设计,样本量较小(改良意向性治疗90例)。
  • 随访时间较短,中位8个月。
  • 脱落6例未接受分配干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary immune thrombocytopenia is an autoimmune bleeding disorder. Preclinical reports suggest that the sialidase inhibitor oseltamivir induces a platelet response in the treatment of immune thrombocytopenia. This study investigated the activity and safety of dexamethasone plus oseltamivir versus dexamethasone alone as initial treatment in adult patients with primary immune thrombocytopenia. METHODS: This multicentre, randomised, open-label, parallel group, phase 2 trial was done in five tertiary medical hospitals in China. Eligible patients were aged 18 years or older with newly diagnosed, treatment-naive primary immune thrombocytopenia. Participants were randomly assigned (1:1), using block randomisation, to receive either dexamethasone (orally at 40 mg per day for 4 days) plus oseltamivir (orally at 75 mg twice a day for 10 days) or dexamethasone monotherapy (orally at 40 mg a day for 4 days). Patients who did not respond to treatment (platelet counts remained <30 × 109 cells per L or showed bleeding symptoms by day 10) were given an additional cycle of dexamethasone for 4 days in each group. Patients in the dexamethasone plus oseltamivir group who relapsed (platelet counts reduced again to <30 × 109 cells per L) after an initial response were allowed a supplemental course of oseltamivir (75 mg twice a day for 10 days). The coprimary endpoints were 14-day initial overall response and 6-month overall response. Complete response was defined as a platelet count at or above 100 × 109 cells per L and an absence of bleeding. Partial response was defined as a platelet count at or above 30 × 109 cells per L but less than 100 × 109 cells per L and at least a doubling of the baseline platelet count and an absence of bleeding. A response lasting for at least 6 months without any additional primary immune thrombocytopenia-specific intervention was defined as sustained response. All patients who were randomly assigned and received the allocated intervention were included in the modified intention-to-treat population analysis. This study has been completed and is registered with ClinicalTrials.gov, number NCT01965626. FINDINGS: From Feb 1, 2016, to May 1, 2019, 120 patients were screened for eligibility, of whom 24 were ineligible and excluded, 96 were enrolled and randomly assigned to receive dexamethasone plus oseltamivir (n=47) or dexamethasone (n=49), and 90 were included in the modified intention-to-treat analysis. Six patients did not receive the allocated intervention. Patients in the dexamethasone plus oseltamivir group had a significantly higher initial response rate (37 [86%] of 43 patients) than did those in the dexamethasone group (31 [66%] of 47 patients; odds ratio [OR] 3·18; 95 CI% 1·13-9·23; p=0·030) at day 14. The 6-month sustained response rate in the dexamethasone plus oseltamivir group was also significantly higher than that in the dexamethasone group (23 [53%] vs 14 [30%]; OR 2·17; 95 CI% 1·16-6·13; p=0·032). During the median follow-up of 8 months (IQR 5-14), two of 90 patients discontinued treatment due to serious adverse events (grade 3); one (2%) patient with general oedema in the dexamethasone plus oseltamivir group and one (2%) patient with fever in the dexamethasone group. The most frequently observed adverse events of any grade were fatigue (five [12%] of 43 in the dexamethasone plus oseltamivir group vs eight [17%] of 47 in the dexamethasone group), gastrointestinal reactions (eight [19%] vs three [6%]), insomnia (seven [16%] vs four [9%]), and anxiety (five [12%] vs three [6%]). There were no grade 4 or 5 adverse events and no treatment-related deaths. INTERPRETATION: Dexamethasone plus oseltamivir offers a readily available combination therapy in the management of newly diagnosed primary immune thrombocytopenia. The preliminary activity of this combination warrants further investigation. Multiple cycles of oseltamivir, as a modification of current first-line treatment, might be more effective in maintaining the platelet response. FUNDING: National Natural Science Foundation of China.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Sun L, Wang J, Shao L, et al. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol. 2021. PMID: 33770484. doi:10.1016/S2352-3026(21)00030-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。